Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Neoplasms 2Lymphoma 2Subcutaneous panniculitis-like T-cell lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × siplizumab × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00806728 2008-12-11

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

MedImmune LLC

Phase 1 Completed
17 enrolled

Graft vs Host Disease, Neoplasms

NCT00105313 2007-06-14

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

MedImmune LLC

Phase 1 Terminated
80 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡